GRIFFITH University researchers from the National Centre for Neuroimmunology and Emerging Disease have demonstrated that the opioid agonist, naltrexone, significantly restored the function of faulty receptors associated with myalgic encephalomyelitis, also known as Chronic Fatigue Syndrome (ME/CFS).
Published in the Frontiers in Immunology journal, the study concluded that naltrexone may have potential for use as a treatment for the seriously debillitating illness ME/CFS, whose aetiology is unknown.
To access the research, visit frontiersin.org.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Nov 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Nov 19
